Mass cytometry papers in COVID from 2020
You will find the list of papers of mass cytometry (CyTOF) investigating COVID-19 in 2020.
We also propose two other reviews, one about mass cytometry data in blood cancers, the other in solid tumors.




05-Jan-2021
Dario Bongiovanni
Materials
8 patients 11 donors
Number of markers
21 markers
Investigation of transmembrane proteins in platelets of hospitalized COVID-19 patients. Non-stimulated platelets compared to stimulated platelets. In COVID patients, significantly reduced capacity of platelets to increase the expression of activation markers LAMP-3 and P-Selectin upon stimulation with TRAP.
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype
Cell Death & Disease
04-Nov-2020
Wen Shi
Materials
5 healthy donors 9 COVID patients
Number of markers
29 markers
Comparison of peripheral blood between HD and COVID patients and identification of CD4 depletion.
High-dimensional single-cell analysis reveals the immune characteristics of COVID-19
Lung cellular and molecular physiology
29-Aug-2020
Jason Neidleman
Materials
9 COVID19 (mild, recovered)
Number of markers
38 markers
Characterisation of T cells from COVID19 recovered patients. SARS-CoV-2-specific CD4+ T cells were exclusively Th1 cells (predominantly Tcm). SARS-CoV-2-
specific CD8+ T cells were predominantly TemRA cells (in less terminal differentiation state). Subsets of SARS-CoV-2-specific T cells express CD127, can homeostatically proliferate, and can persist for over two months.
SARS-CoV-2-specific T cells exhibit phenotypic features of robust helper function,
lack of terminal differentiation, and high proliferative potential
Cell Reports Medicine
26-Aug-2020
Tal Goshen-Lago
Materials
164 cancer patients and 107 healthcare workers
Number of markers
39 markers
Due to differential immune cell profile of cancer patients who are treated with immunomodulatory agents, the host response to the SARS-COV2 may lessen symptom severity.
The Potential Role of Immune Alteration in the Cancer–COVID19 Equation—A Prospective Longitudinal Study
Cancers
25-Aug-2020
Lucie Rodriguez
Materials
37 COVID19, and follow-up with 14 patients
Number of markers
48 markers
Characterisation of the immune response to COVID19 over time in the blood. IFNγ-eosinophil axis activated before lung hyperinflammation
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19
Cell Reports Medicine
11-Aug-2020
Prabhu S. Arunachalam
Materials
76 COVID-19 patients and 69 healthy individuals from Hong Kong and Atlanta
Number of markers
34 markers
Analysis of immune responses in between COVID-19 patients and healthy individuals from Hong Kong and Atlanta
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
Science
11-Aug-2020
Yingfeng Zheng
Materials
5+2 young healthy adults, 5+2 aged healthy adults, 2 young and 2 aged COVID19 patients
Number of markers
31 markers
Combined scRNA-seq, mass cytometry and scATAC-seq to compare immune cell types in peripheral blood collected from young and old subjects and patients with COVID-19
A human circulating immune cell landscape in aging and COVID-19
Protein& Cell
5-Aug-2020
Jonas Schulte-Schrepping
Materials
40 COVID19, 8 Flu-like illness, 10 controls
Number of markers
55 markers in 2 panels
Integration of multiple platforms to study COVID19 over time showing:
- Mild COVID-19 corrolates with HLA-DRhiCD11chi CD14+ monocytes
- Severe COVID-19 corrolates with HLA-DRloCD163hi and HLA-DRloS100Ahi CD14+ monocytes
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Cell
18 July 2020
Lindsey E. Padgett
Materials
30 convalescent patients with mild, moderate, and severe cases of COVID-19
Number of markers
41 markers
Mass cytometry to investigate peripheral myeloid cells and T lymphocytes from 30 convalescent patients with mild, moderate, and severe cases of COVID-19. CD14+CD16+ intermediate and CD14dimCD16+ nonclassical monocytes, as well as CD4+ stem cell memory T (TSCM) cells, correlated with COVID-19 severity. Both intermediate and non-classical monocyte subsets shape the adaptive immune response to SARS-CoV-2
Interplay of Monocytes and T Lymphocytes in COVID-19 Severity
BioRXiv
13 July 2020
Jérôme Hadjadj
Materials
50 COVID-19 patients and 18 healthy controls
Number of markers
30 markers
Highly impaired IFN response (characterized by no IFN-β and low IFN-α production and activity) was found to be associated with a persistent blood viral load. Type-I IFN deficiency in blood could be a hallmark of severe COVID-19.
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Science
29 June 2020
Daniel Geanon
Materials
19 COVID-19 patients
Number of markers
30 markers
Validation of a workflow for staining of whole blood samples with minimal processing requirements or expertise at the site of sample collection, followed by shipment to a central CyTOF core facility for batched downstream processing and data acquisition. Characterization of immune responses of COVID-19 patients, highlighting key disease-associated changes in immune cell frequency and phenotype.
A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients
medRXiv
16 June 2020
Lin‐lin Wei
Materials
6 critical COVID‐19
Number of markers
33 markers
Mass cytometry to study COVID-19 patients. Good prognoses had significantly higher counts of monocytes, macrophages, higher frequency of CD3+CD4+CD45RO+CXCR3+ subsets, higher frequency of CD14+CD11C+HLA‐DR+ subset of dendritic cells and a lower count of neutrophils. Proportions of naïve CD4+ T cells, Tregs, and Th2 cells in the poor prognosis group were relatively higher than those in the good prognosis group, and CD4+ memory T cells were relatively lower.
Dysregulation of the immune response affects the outcome of critical COVID‐19 patients
Journal of Medical Virology
28 April 2020
Wenjing Wang
Materials
12 PBMCs from healthy donors and 12 from COVID-19 patients
Number of markers
36 markers
Mass cytometry profiled immune cellular components to analyze the peripheral blood mononuclear cells (PBMCs) from patients with differences in disease progression by comparing with the PBMCs from healthy donors (HDs).
High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients
Cellular & Molecular Imunology
Materials
Number of markers